MCET
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2015 Q3 | -0.03 | $195 | -$79 |
| 2015 Q2 | 0.03 | $586 | $306 |
| 2015 Q1 | -0.00 | $12 | -$126 |
| 2014 Q4 | -0.00 | $12 | -$299 |
| 2014 Q3 | 0.04 | $12 | -$214 |
| 2014 Q2 | -0.00 | $12 | -$368 |
| 2014 Q1 | -0.00 | $12 | -$207 |
| 2013 Q4 | -0.00 | $12 | -$383 |